ProCE Banner Activity

Pharmacists Discuss Key HCP Questions on BTK Inhibitors

Clinical Thought

In this short commentary, expert pharmacists respond to frequently asked questions from HCPs on best practices in the use of BTK inhibitors for CLL and MCL.

Released: December 23, 2022

Expiration: December 22, 2023

No longer available for credit.

Share

Faculty

Karen M. Fancher

Karen M. Fancher, PharmD, BCOP

Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania

Anthony Perissinotti

Anthony Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
Clinical Team Leader
, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan

Supporters

Supported by an educational grant from

Pharmacyclics LLC, an AbbVie Company

Partners

National Association of Specialty Pharmacy

ProCE Banner